Enanta Pharmaceuticals | ENTA - DEBITO





DEBITO Cambiamento Data
AbbVie USD 72.86B 5.36B 2026-03
Amgen USD 57.32B 2.72B 2026-03
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 983.69M 5.77M 2026-06
AstraZeneca USD 32.24B 1.68B 2026-06
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Biogen USD 8.09B 1.53B 2026-06
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 22.17B 2.76B 2026-03
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Heron Therapeutics USD 149.65M 157K 2024-09
Immunic USD 0 0 2024-06
Incyte USD 38.27M 1.16M 2026-06
Insmed USD 725.8M 1.82M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
J&J USD 54.99B 7.05B 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451.98M 486K 2026-03
Merck USD 49.12B 222M 2026-03
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 49.01B 2.02B 2026-06
Novavax USD 233.31M 4.23M 2024-09
Pfizer USD 63.19B 536M 2026-06
PTC Therapeutics USD 286.94M 2.42B 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
Vertex Pharmaceuticals USD 1.98B 8.9M 2026-06